Autoimmune nodopathies: treatable neuropathies beyond traditional classifications.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies.Frontiers in neurology · 2025
   Review
2. Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.European journal of neurology · 2024
   Article
3. Advances in diagnosis and management of distal sensory polyneuropathies.Journal of neurology, neurosurgery, and psychiatry · 2023
   Review
4. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
   Review

Corrections and comments

• Comment on
  IgG2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as